Rxrx stock forecast.

Next reporting date: February 14, 2024: EPS forecast (this quarter) $0.95: Annual revenue (last year) $2.2B: Annual profit (last year) $42.8M: Net profit marginWall Street Analysts Forecast Growth. RXRX has been the topic of several research reports. Needham & Company LLC dropped their target price on Recursion …Throughout the U.S., the weather can be quite unpredictable, even with state-of-the-art radar, sensors and computer modeling technology right at meteorologists’ fingertips. The Old Farmer’s Almanac first provided valuable statistics and dat...What are analysts forecasts for Recursion Pharmaceuticals, stock? The 21 analysts offering price forecasts for Recursion Pharmaceuticals, have a median target of 14.62, with a high estimate of 33. ...

Jul 13, 2023 · Recursion Pharmaceuticals, Inc. (RXRX) : Free Stock Analysis Report. Omega Therapeutics, Inc. (OMGA) : Free Stock Analysis Report ... according to the forecast. 7h ago. Zacks. 2 Stocks to Buy from ... Analyst Future Growth Forecasts. Earnings vs Savings Rate: RXRX is forecast to remain unprofitable over the next 3 years. Earnings vs Market: RXRX is …

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET.Nov 22, 2023 · The company's shares are currently changing hands for $7.07 apiece, but the consensus one-year target for the stock is $15.57, which implies that it could rise by about 120% over the next 12 months.

Recursion Pharma (NASDAQ: RXRX) made waves this week. ... AMZN Stock Forecast: Predicting Amazon's Performance in 2023 and Beyond Stocks to Buy Nov 21, 2023 3 Stocks to Buy With Your Holiday Bonus ...Nov 28, 2023 · The Baudax Bio Inc stock price gained 31.73% on the last trading day (Friday, 24th Nov 2023), rising from $0.0646 to $0.0851. During the last trading day the stock fluctuated 41.83% from a day low at $0.0600 to a day high of $0.0851. The price has fallen in 6 of the last 10 days and is down by -54.02% for this period. What this means: Recursion Pharmaceuticals Inc Cl (RXRX) gets an Overall Rank of 60, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value.Wall Street Analysts Forecast Growth. RXRX has been the topic of several research reports. Needham & Company LLC dropped their target price on Recursion …Recursion Pharmaceuticals (NASDAQ: RXRX) stock popped in July, fueled by a game-changing development—a direct investment of $50 million from Nvidia. But, since that month’s peak, RXRX’s ...

Find the latest Insider Activity data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.

InvestorsObserver is giving Recursion Pharmaceuticals Inc (RXRX) an Analyst Rating Rank of 25, meaning RXRX is ranked higher by analysts than 25% of …

Should You Buy or Sell Recursion Pharmaceuticals Stock? Get The Latest RXRX Stock Analysis, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.What's going on at Recursion Pharmaceuticals (NASDAQ:RXRX)? Read today's RXRX news from trusted media outlets at MarketBeat. Skip to main content. S&P 500 4,594.63 (+0.59%) DOW 36,245.50 (+0.82%) ... Stock Analysis Analyst Forecasts Chart Competitors Earnings Financials Headlines Insider Trades Ownership SEC Filings …(See RXRX stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy , a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analyst.Cathie Wood’s ARK Investment bought 1.89M shares of Recursion Pharmaceuticals November 27, 2023TipRanks. Analysts Offer Insights on Healthcare Companies: Recursion Pharmaceuticals (RXRX ...With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.5 analysts have issued 12 month price objectives for Amneal Pharmaceuticals' stock. Their AMRX share price targets range from $3.00 to $7.00. On average, they anticipate the company's share price to reach $4.80 in the next year. This suggests a possible upside of 9.3% from the stock's current price.Zillow is worth $8.3 billion right now, so if it reaches its 2025 sales estimate and continues to grow thereafter, it should breeze past a $10 billion valuation by 2030. 2. Duolingo: Potential ...

4.31%. €8.59M. RXRX | Complete Recursion Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.The US$14.13 analyst price target for RXRX is 3.5% less than our ... we will estimate the stock's intrinsic value by taking the forecast future cash flows of the company and discounting ...RXRX stock does seem to be getting support at the 200-day moving average, at least for now. Wood also trimmed her holdings of Shopify in her flagship ARK Innovation ETF by just over 182,000 shares ...RXRX has gained $0.29 from the previous closing price of $5.16 on volume of 1,340,878 shares. Over the past year the S&P 500 is higher by 3.38% while RXRX is lower by -1.98%. RXRX lost -$1.36 per share the over the last 12 months. Click Here to get the full Stock Report for Recursion Pharmaceuticals Inc stock.The Xerox Corporation stock price gained 1.29% on the last trading day (Friday, 1st Dec 2023), rising from $13.99 to $14.17. During the last trading day the stock fluctuated 4.56% from a day low at $13.60 to a day high of $14.22. The price has risen in 6 of the last 10 days and is up by 4.34% over the past 2 weeks.At the time of writing, Recursion Pharmaceuticals Inc [RXRX] stock is trading at $6.11, up 10.49%. It is a good measure of the stock's recent performance to check whether the stock's short-term value is rising or falling. The RXRX shares have gain 15.72% over the last week, with a monthly amount drifted -9.62%, and not

The consensus price target of analysts on Wall Street is $16.00, which implies an increase of 65.31% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $9.00 and $35.00 respectively. As a result, RXRX is trading at a discount of -530.63% off the target high and -62.16% off the low.Find the latest RxSight, Inc. (RXST) stock quote, history, news and other vital information to help you with your stock trading and investing.

gguy44. Recursion Pharmaceuticals ( NASDAQ: RXRX) is up 17% on Wednesday in much higher than usual volume as it may be in a short squeeze situation. As of 1215p ET, volume was ~16.6M shares ...4.31%. €8.59M. RXRX | Complete Recursion Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.U.S. crude futures finish 1.2% higher $75.75 a barrel, the highest closing price since April 28, while Brent crude finishes above $80 for the first time since April 25, ending at $80.11. "Crude ...First on the list of Cathie Wood stocks is Archer Aviation (NYSE: ACHR ), which is swiftly carving out its name as a juggernaut in the realm of flying cars. Its stock has been on fire this year ...Always seek sound financial advice from your consultant or financial advisor before investing in the stock market. I am a grapefruit, and the stock market is a casino. Disclosure: No positions current in this stock, planning to go Long, likely for between 100 to 500 shares.Recursion Pharmaceuticals, Inc. Analyst Report: Pfizer Inc. Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales ... Recursion Pharmaceuticals Inc Cl A stocks price quote with latest real-time prices, charts, financials, ... RXRX Related stocks. Symbol 3M %Chg ; RXRX -18.97% : Recursion Pharmaceuticals Inc Cl A: ZTS -6.96% : Zoetis Inc Cl A: TAK ... Cash Markets Overview Corn Indexes Soybean Indexes Yield Forecast Indexes.Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel ...Future criteria checks 0/6. Recursion Pharmaceuticals's revenue and earnings are forecast to decline at 2.9% and 12.8% per annum respectively. EPS is expected to decline by 9% per annum. Return on equity is forecast to be -471.6% in 3 years.

Recursion Pharmaceuticals, Inc. Analyst Report: Pfizer Inc. Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales ...

Recursion Pharmaceuticals Stock Prediction. BSX. 63

If you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up to date on the world markets.View the latest Recursion Pharmaceuticals Inc. (RXRX) stock price, news, historical charts, analyst ratings and financial information from WSJ. Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...The above table shows the analyst RXRX forecast and predictions for the stock price in 12 month’s time. Date Share Price Average 1Y Price Target Dispersion High Low 1Y Actual price Analysts; Current: US$7.39On May 8, Recursion Pharmaceuticals (RXRX 7.88%) announced that it was going to buy a pair of AI-enabled drug discovery biotechs, Cyclica and Valence, for a total of $87.5 million -- paid in stock.Find the latest Recursion Pharmaceuticals, Inc. (RXRX) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.Get free stock tools, free stock ratings, free stock charts and calculate the value of stocks to buyWall Street Analysts Forecast Growth. RXRX has been the topic of several research reports. Needham & Company LLC dropped their target price on Recursion …

NVIDIA Corporation Common Stock. $416.10 +5.93 +1.45%. ARM. Arm Holdings plc American Depositary Shares. $51.32 -0.84 -1.61%. Find the latest analyst research for Recursion Pharmaceuticals, Inc ...The 7 analysts offering 1 year price forecasts for RXRX have a max estimate of — and a min estimate of —. Analyst rating Based on 7 analysts giving stock ratings to RXRX in the past 3 months. how to read an earnings report. Nasdaq provides visual representation of analyst expected earnings growth. Read our earnings report guide before you consider the forecast information when making ...The 7 analysts offering 1 year price forecasts for RXRX have a max estimate of — and a min estimate of —. Analyst rating Based on 7 analysts giving stock ratings to RXRX in the past 3 months. Instagram:https://instagram. home inventory software freeone cent 2009 valuecoke dividenduber stock forecast Recursion Pharmaceuticals shares have jumped some 80% on Wednesday. The biotech company said that Nvidia is investing $50 million to boost Recursion’s drug-discovery companies. Recursion’s ... best gold sales companiesfinancial planner okc Analysts on Wall Street sometimes assign one-year price targets to stocks that imply massive upside potential. That's what's happening with Recursion …See Recursion Pharmaceuticals, Inc. (RXRX) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. best leveraged etf We've seen plenty of personal finance tools designed to help you track what you're spending, but web site PocketSmith is an impressive new web-based personal finance tool with an emphasis on forecasting your financial future. We've seen ple...With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.